Methods of treating inflammation using mammalian CX
View Patent ↗Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
1. A method for treating inflammation, which is mediated by chemoattraction of peripheral blood monocytes or T-cells, in a subject comprising administering, to said subject, an effective dose of an isolated antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof comprising said antibody or antigen-binding fragment and a pharmaceutically acceptable carrier, which antibody or antigen-binding fragment specifically binds to a polypeptide wherein said polypeptide
a) chemoattracts peripheral blood monocytes or T-cells,
b) consists of an amino acid sequence comprising at least 95% sequence identity to residues 25 to 395 of the amino acid sequence set forth in SEQ ID NO: 8, and
c) comprises a chemokine domain identical to residues 25 to 100 of the amino acid sequence set forth in SEQ ID NO: 8.
2. The method of claim 1 wherein said isolated antibody or antigen-binding fragment thereof specifically binds to a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 8.
3. The method of claim 1 wherein said isolated antibody or antigen-binding fragment thereof specifically binds to a polypeptide consisting of Gln25 to Gly100 of the amino acid sequence set forth in SEQ ID NO: 8.
4. The method of claim 1 wherein said polypeptide is denatured.
5. The method of claim 3 wherein said isolated antibody or antigen-binding fragment thereof is produced in a process comprising immunizing an animal with a purified or recornbinantly produced polypeptide comprising Gln25 to Gly100 of the amino acid sequence set forth in SEQ ID NO: 8.
6. The method of claim 5 wherein said isolated antibody or antigen-binding fragment thereof is produced in a process comprising immunizing an animal with a purified or recombinantly produced polypeptide comprising a mature polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8.
7. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is detectably labeled.
8. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is an antibody and the antibody is a polyclonal antibody.
9. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is an antibody and the antibody is a monoclonal antibody.
10. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is a fragment and the fragment is a Fab.
11. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is a fragment and the fragment is a F(ab) 2 .
12. The method of claim 1 wherein the antibody or antigen-binding fragment thereof is sterile.
13. The method of claim 1 wherein the antibody or antigen-binding fragment thereof exhibits a K D to said polypeptide of greater than about 100 nM.
14. The method of claim 1 wherein the antibody or antigen-binding fragment thereof exhibits a K D to said polypeptide of greater than about 30 nM.
15. The method of claim 1 wherein the antibody or antigen-binding fragment thereof exhibits a K D to said polypeptide of greater than about 10 nM.
16. The method of claim 1 wherein the antibody or antigen-binding fragment thereof exhibits a K D to said polypeptide of greater than about 3 nM.
17. The method of claim 1 for treating inflammation which is mediated by chemoattraction of peripheral blood monocytes or T-cells, in a subject comprising administering, to said subject, an effective dose of a pharmaceutical composition comprising the antibody or antigen-binding fragment of and a pharmaceutically acceptable carrier.
18. A method for treating inflammation, which is mediated by chemoattraction of peripheral blood monocytes or T-cells, in a subject comprising administering, to said subject, an effective dose of a monoclonal antibody that binds specifically to a polypeptide consisting of amino acids 25-395 of SEQ ID NO: 8, or a pharmaceutical composition thereof which comprises a pharmaceutically acceptable carrier.
19. A method for treating inflammation which is mediated by chemoattraction of peripheral blood monocytes or T-cells, in a subject comprising administering, to said subject, an effective dose of a pharmaceutical composition comprising a monoclonal antibody that binds specifically to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 8 and a pharmaceutically acceptable carrier.